Moebius Medical
Tel Aviv, Israel· Est.
Moebius Medical leverages liposomal delivery to create a long‑acting, disease‑modifying intra‑articular therapy for osteoarthritis.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Moebius Medical leverages liposomal delivery to create a long‑acting, disease‑modifying intra‑articular therapy for osteoarthritis.
Osteoarthritis
Technology Platform
Proprietary large empty multilamellar liposome (LML‑Lipo) technology enabling sustained intra‑articular delivery of non‑opioid agents with cartilage‑protective effects.
Opportunities
Successful Phase 3 data could unlock a multi‑billion‑dollar OA market and enable expansion into other joints or combination therapies.
Risk Factors
Clinical failure or regulatory setbacks, reliance on a single product, and competition from established steroid/HA injections and emerging disease‑modifying OA agents.
Competitive Landscape
Competes with steroids, hyaluronic acid, and emerging liposomal or biologic OA treatments; Moebius differentiates via longer durability, non‑opioid mechanism, and cartilage‑protective properties.